FDA approves Novartis Beovu ® injection to treat wet macular degeneration
-
Last Update: 2020-06-08
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
Novartis(http:// announcedthat the U.SFooddrug(http://Regulatory Authority (
FDA(http://) approved the Beovu ® , also known as RTH258, for the treatment of age-related wet macular degenerationAbout Beovu
Beovu was the first FDA-approved anti-VEGFdrug(http://that reduced fluid build-up compared to aflibercept After a three-month load period, the drug was given for three months, and the efficacy was not affected Beovu's approval is based on the results of the (http:// of the Phase III HAWK and HARRIER Clinical Trials, in which Beovu showed a correlation between non-performance and aflibercept in the average change in optimal corrective visual athemito (BCVA) in the first year (week 48) In the HAWK and HARRIER trials, Beovu first showed a greater reduction in central sub-field thickness (CST) in the 16th week of the first year, and fewer patients in the retina (IRF) and/or sub-retinal fluid (SRF) Retinopathy is a key marker of disease activity
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
